Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Staar Surgical Aqua-Flow

This article was originally published in The Gray Sheet

Executive Summary

Premarket approval application submission for the collagen glaucoma drainage device is announced July 6. Clinical data included in the filing show a mean reduction of intraocular pressure from 24.2 mm Hg before placement to 16.5 mm Hg at one-year follow-up. Patients also experienced a mean drop in pressure controlling medications from 2.3 to 0.3, the firm says. Physician training is scheduled to begin in August
Advertisement

Related Content

Staar Surgical AquaFlow Glaucoma Drainage Device Approvable - FDA Panel
Staar Surgical AquaFlow Glaucoma Drainage Device Approvable - FDA Panel
Advertisement
UsernamePublicRestriction

Register

MT013606

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel